AXIM (AXIM Biotechnologies) Equity-to-Asset: -3.23 (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is AXIM Biotechnologies Equity-to-Asset?

AXIM Biotechnologies AXIM +2.56% Equity-to-Asset is -3.23 as of Jun. 2025. Among 1,416 Biotechnology companies, AXIM Biotechnologies ranks worse than 96.54% on this metric.

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. AXIM Biotechnologies's Total Stockholders Equity for the quarter that ended in Jun. 2025 was $-10.43 Mil. AXIM Biotechnologies's Total Assets for the quarter that ended in Jun. 2025 was $3.22 Mil.

The historical rank and industry rank for AXIM Biotechnologies's Equity-to-Asset or its related term are showing as below:

AXIM's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.68
* Ranked among companies with meaningful Equity-to-Asset only.

AXIM Biotechnologies  (OTCPK:AXIM) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

AXIM Biotechnologies Equity-to-Asset Related Terms

AXIM Biotechnologies Equity-to-Asset Historical Data

* Premium members only.

The historical data trend for AXIM Biotechnologies's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AXIM Biotechnologies Equity-to-Asset Chart

AXIM Biotechnologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 -0.44 -1.15 -1.86 -3.02

AXIM Biotechnologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.89 -2.56 -3.02 -3.18 -3.23

AXIM vs ZVSA, HEPA, ISCO: Equity-to-Asset Comparison

For the Biotechnology subindustry, AXIM Biotechnologies's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AXIM Biotechnologies Equity-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where AXIM Biotechnologies's Equity-to-Asset falls into.


AXIM Biotechnologies Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

AXIM Biotechnologies's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Equity to Asset (A: Dec. 2024 )=Total Stockholders Equity/Total Assets
=-10.42/3.447
=-3.02

AXIM Biotechnologies's Equity to Asset Ratio for the quarter that ended in Jun. 2025 is calculated as

Equity to Asset (Q: Jun. 2025 )=Total Stockholders Equity/Total Assets
=-10.426/3.224
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Equity-to-Asset →
What does a Equity-to-Asset of -3.23 mean?
AXIM Biotechnologies (AXIM) has a Equity-to-Asset of -3.23 as of Jun. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on AXIM Biotechnologies and its competitors. According to the industry distribution chart, AXIM Biotechnologies ranks #1367 out of 1416 companies in the Biotechnology industry, placing it in the top 96.5%.
Is AXIM Biotechnologies' Equity-to-Asset too high?
AXIM Biotechnologies' current Equity-to-Asset is -3.23. Based on the distribution chart, AXIM Biotechnologies ranks #1367 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does AXIM Biotechnologies' Equity-to-Asset compare to ZVSA and HEPA?
According to the Biotechnology industry distribution chart, AXIM Biotechnologies ranks #1367 out of 1416 companies for Equity-to-Asset. This places AXIM Biotechnologies in the lower half of its industry. The industry median Equity-to-Asset is 0.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on AXIM Biotechnologies and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AXIM Biotechnologies's current Equity-to-Asset is -3.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AXIM Biotechnologies stock overvalued right now?
AXIM Biotechnologies (AXIM) has a current Equity-to-Asset of -3.23. The current Equity-to-Asset is -3.23. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For AXIM Biotechnologies (AXIM), the current Equity-to-Asset is -3.23 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AXIM Biotechnologies Business Description

Address 6048 Cornerstone Court West, Suite E1, San Diego, CA, USA, 92121
AXIM Biotechnologies Inc is a integrated research and development company and developer of diagnostic healthcare solutions serving to enhance the health of people. The company focuses on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.